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BACKGROUND: When testing for prostate cancer, as many as 75% of men with a raised prostate-specific antigen (PSA) have a benign
biopsy result. Little is known about the psychological effect of this result for these men.
METHODS: In all, 330 men participating in the prostate testing for cancer and treatment (ProtecT) study were studied; aged 50–69
years with a PSA level of X3ngml
 1 and a negative biopsy result. Distress and negative mood were measured at four time-points:
two during diagnostic testing and two after a negative biopsy result.
RESULTS: The majority of men were not greatly affected by testing or a negative biopsy result. The impact on psychological health was
highest at the time of the biopsy, with around 20% reporting high distress (33 out of 171) and tense/anxious moods (35 out of 180).
Longitudinal analysis on 195 men showed a significant increase in distress at the time of the biopsy compared with levels at the PSA
test (difference in Impact of Events Scale (IES) score: 9.47; 95% confidence interval (CI) (6.97, 12.12); Po0.001). These levels
remained elevated immediately after the negative biopsy result (difference in score: 7.32; 95% CI (5.51, 9.52); Po0.001) and 12
weeks later (difference in score: 2.42; 95% CI (0.50, 1.15); P¼0.009). Psychological mood at the time of PSA testing predicted high
levels of distress and anxiety at subsequent time-points.
CONCLUSIONS: Most men coped well with the testing process, although a minority experienced elevated distress at the time of biopsy
and after a negative result. Men should be informed of the risk of distress relating to diagnostic uncertainty before they consent to
PSA testing.
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Prostate cancer is a serious public health problem, motivating
research to determine whether population screening is effective. The
recent publication of two randomised controlled trials still leaves the
benefits of screening uncertain and controversial (Andriole et al,
2009; Schro ¨der et al, 2009), with the European Association of
Urology currently not recommending screening as a public health
policy (Abrahamsson et al, 2009). Regardless of the lack of evidence,
prostate-specific antigen (PSA) testing in asymptomatic men
continues to rise (Melia et al, 2004; Collin et al,2 0 0 8 ) .
Uncertainties remain about the predictive validity of PSA tests,
and their ability to identify tumours that will progress to cause
morbidity and mortality (Frankel et al, 2003; Holmstrom et al,
2009). Arbitrary thresholds (commonly 3 or 4ngml
 1) are used to
recommend referral for biopsy. PSA levels are affected by
measurement error and conditions other than prostate cancer, so
it is not uncommon for PSA levels to rise and fall (Rosario et al,
2008). For these reasons, a high proportion of men with a raised
PSA go on to receive a negative biopsy result – for example, 75%
of men with a PSA test of X3ngml
 1 who had a biopsy in the
European Randomised Study of Screening for Prostate Cancer
(Schro ¨der et al, 2009).
Consequently, many men who have a PSA test (and their
physicians) may be left to cope with uncertain results. Increases in
negative mood have been found in studies of women with
abnormal but benign results for breast (Lowe et al, 1999; Aro
et al, 2000) and ovarian (Andrykowski et al, 2004) cancer.
Although studies of men undergoing PSA testing have shown no
significant effect on anxiety for those receiving an abnormal PSA
result (Essink-Bot et al, 1998; Brindle et al, 2006; Carlsson et al,
2007), it has been reported that those who receive a benign biopsy
have thought and worried more aboutp r o s t a t ec a n c e r( M c N a u g h t o n -
Collins et al, 2004; Fowler et al, 2006; Katz et al, 2007). However,
these latter studies were small and relied on unvalidated measures
for these outcomes. We aimed to assess the prevalence and level of
psychological distress and negative mood at several time-points
during population-based testing for prostate cancer, focusing on
men who received a negative biopsy result, using validated and
standardised questionnaires. Baseline data were explored to
investigate whether men vulnerable to heightened distress could
be identified early in the testing process.
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sMATERIALS AND METHODS
Participants
Participants in this study were men enrolled in the Prostate testing
for cancer and Treatment (ProtecT) study, a randomised trial of
treatment for localised prostate cancer (Donovan et al, 2003). Men
aged 50–69 years were invited from general practices across nine
sites in the United Kingdom to attend for PSA testing. Those with a
raised PSA level (X3ngml
 1) were offered a transrectal ultra-
sound-guided biopsy carried out by an urologist to a standard
10-core protocol at the local hospital. Men diagnosed with
clinically localised cancer were eligible for randomisation to one
of the three treatments. Between June 2007 and September 2008,
men receiving a negative biopsy result (with no immediate
requirement for a re-biopsy) were identified for this substudy,
by local research nurses from eight of the UK sites.
Approval for the ProtecT study was obtained from Trent Multi-
centre Research Ethics Committee. Written informed consent was
provided by all participants.
Measures
Mood and psychological distress were assessed at four time-points
by patient-completed questionnaires: (1) when attending for the
first PSA test (before the result was known); (2) when attending
for biopsy (in clinic before the procedure); (3) within a few days
of receiving the negative biopsy result (postal questionnaire,
completed at home) and (4) B12 weeks later (postal question-
naire, for those who returned a questionnaire at time-point 3) (see
Figure 1). One reminder was posted if questionnaires were not
returned within 10 working days.
Current states of mood were assessed by the Profile of Mood
States – short form (POMS-SF) (Shacham, 1983), a 37-adjective
checklist rated on a 5-point scale (0¼‘not at all’ to 4¼
‘extremely’). Responses to items were totalled, providing six
subscale scores for tension-anxiety (maximum score¼24), depres-
sion-dejection (maximum score¼32), anger-hostility (maximum
score¼28), fatigue-inertia (maximum score¼20), vigour-activity
(maximum score¼24) and confusion-bewilderment (maximum
score¼20). Distress was measured by the Impact of Events Scale
(IES) (Horowitz et al, 1979); in which seven items formed an
intrusion subscale and eight an avoidance subscale, scored 0¼‘not
at all’, 1¼‘rarely’, 3¼‘sometimes’, 5¼‘often’, and collated to give
an overall score (maximum score¼75). Questions were adapted to
assess the frequency of intrusive thoughts and avoidance of issues
surrounding the specific event of that time-point: the PSA test, the
biopsy, the negative biopsy result and, for the follow-up
assessment, being tested for prostate cancer overall. For example:
‘I tried not to think about the PSA blood test’ (time-point 1); ‘I
tried not to think about going for my biopsy’ (time-point 2); ‘I
tried not to think about getting my biopsy results’ (time-point 3)
and ‘I tried not to think about being tested for prostate cancer’
(time-point 4). Written instructions informed men to respond
about their feelings during the past week, including that day.
Both measures have previously been used in studies investigating
the effect of cancer screening (Taylor et al, 2002; Andrykowski
et al, 2004).
Missing data
Multiple responses to an individual item on the POMS ques-
tionnaire were considered as errors and treated as missing values.
Single missing values within a subscale were replaced with the
(†n = 133)
(†n = 180)
(†n = 294)
(†n = 299)
Attendance for PSA
test following invitation
Raised PSA
≥3 ng ml–1
Normal PSA
< 3 ng ml–1 
Attendance for
biopsy
Refuse biopsy 
Positive result  Negative
biopsy result
Post negative result (3)
PSA test (1)
Biopsy (2)
Repeat biopsy
required
Follow-up 
12 week follow-up (4)
Questionnaire time-points
†Number of men with complete questionnaire data
Randomised for treatment within
ProtecT (prostate testing for cancer
and treatment) study
Timeframe
(median days) 
0
52
98
199
Completed by men in clinic
when attending for testing
Completed by men in clinic
when attending for biopsy
Completed by men at home 
on receipt of negative biopsy 
result
Completed by men at home
12 weeks after negative
biopsy result   
Figure 1 Outline of study design and assessment time-points.
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(184 imputations, o1% of total responses). In cases of two or
more missing values, no score was calculated for that POMS
subscale. Missing items on the IES resulted in no subscale score or
total score. This substudy was embedded in the ProtecT trial and
as the POMS and IES were added in an amendment to the original
protocol, some men identified with a negative biopsy result
had completed time-points 1 and 2 before the measures were
introduced, resulting in lower numbers of men completing the
measures at earlier time-points (see Figure 1).
Statistical analyses
High levels of psychological distress were determined using
established cutoff thresholds: for IES, a total score of 419 (Joseph,
2000); for POMS negative mood subscales, 1.5 s.d. above the mean
at PSA testing (time-point 1) (Nyenhuis et al, 1999). Change in
mood over time was examined in those men who completed all of
the questionnaires they were sent (n¼195); this included men who
had already undergone PSA testing and biopsy when this substudy
started and so had their earlier questionnaire responses missing
completely at random. T-tests compared the scores at PSA test for
this cohort of men to those who completed questionnaires at PSA
test but not all of the subsequent assessments. For longitudinal
analyses, linear regression models with questionnaire subscale
scores as outcome measures were fitted using Stata 10. Models
compared questionnaire scores at the subsequent time-points to
responses at PSA test (time-point 1). P-values were calculated
using parametric bootstrap estimates of the s.e. (Davison and
Hinkley, 1997). Confidence intervals (CIs) were calculated using
the percentile bias corrected and accelerated bootstrap method.
A total of 1999 bootstrap samples were obtained by re-sampling
men from the study sample with replacement, so accommodating
the repeated measures design and any non-normality in the
distributions of outcome measure. Because of the extreme positive
skew of IES scores, a sensitivity analysis used logistic regression
of dichotomised scores (no distress symptoms/at least some
symptoms).
A secondary analysis examined cases of heightened distress (IES
total score) and high anxiety (POMS tension-anxiety score) at
attendance for biopsy and after having received a negative biopsy
result, and explored potential predictors: demographic (age, family
history of prostate cancer and any cancer), clinical (PSA level,
lower urinary tract symptoms: frequency, urgency, incontinence,
nocturia, hesitancy and interference with everyday life) and
psychological (baseline POMS anxiety and IES avoidance and
intrusion subscale scores). Univariable logistic regression models
were fitted to examine each of these 13 baseline measures in turn
as a predictor of high distress and anxiety at later time-points in
the testing process.
RESULTS
In total, 330 men were contacted after a negative biopsy result.
Table 1 shows their clinical and demographic details. The response
rate for postal questionnaires was 91.8% after the negative biopsy
result (time-point 3) and 82.6% at the 12-week follow-up (time-
point 4). Non-responders were significantly younger than respon-
ders at both time-points (P¼0.016, P¼0.006, respectively). After
accounting for non-responders and missing responses on ques-
tionnaire items, data were available from 294 out of 330 and 229
out of 287 men, respectively (only those who responded at time-
point 3 were sent a follow-up questionnaire, and during one week
men were not posted questionnaires due to an administrative
error, thus reducing the denominator to 287). POMS and IES data
were available for 133 out of 330 of the study sample at PSA
assessment (time-point 1), and for 180 out of 330 at biopsy
assessment (time-point 2) – smaller numbers due to introducing
the measures part-way through the ProtecT study. Figure 1 shows
average time (median number of days) between assessments.
Overall, rates of psychological distress (IES scores) and negative
mood (POMS scores) were relatively low at all time-points, with
around 80–95% of individuals reporting levels below the clinical
threshold at each stage (Table 2). However, nearly one fifth of men
(19.4%) reported high levels of tension-anxiety at the time of
attending for the biopsy (time-point 2), and 8.9% after the negative
biopsy result (time-point 3). The proportion of men with a distress
level of clinical concern was markedly higher at the time of biopsy
compared with distress at the time of the PSA test (19.3, 0.8%,
respectively). This percentage decreased only slightly after the
negative biopsy result (16.9%), and 9.7% were distinctly distressed by
the testing process after 12 weeks. Reports of high depression-
dejection (7.5%), anger-hostility (6.8%), fatigue-inertia (12%) and
confusion-bewilderment (8.3%) were most prevalent at the time of the
PSA test, whereas they were o5% by the 12-week follow-up (Table 2).
Within the study sample, 195 men responded to all ques-
tionnaires they were sent, with POMS and IES scores missing for
one or both of the first two assessments only if the man joined
the study before these measures were introduced. These earlier
assessments at time-points 1 and 2 were assumed to be missing at
random, enabling changes in mood over the course of the testing
process to be observed without confounding by determinants of
non-response (Table 3). This cohort had similar clinical and
demographic distributions to that of the complete sample (Table 1).
At the time of the biopsy, a significant increase in tense and
anxious moods was apparent (difference in mean: 2.07; 95% CI
(1.35, 2.83); Po0.001), and men experienced significantly more
distress (difference in mean IES total score: 9.47; 95% CI (6.97,
12.12); Po0.001). After receiving a negative biopsy result, scores
for tense and anxious moods returned to levels similar to those
recorded at the PSA test. However, reports of distress were
significantly higher than at the time of the PSA test (difference in
Table 1 Clinical and demographic information for the whole study sample and the longitudinal cohort
Whole study sample (n¼330) Longitudinal cohort (n¼195)
Summary statistic Range Summary statistic Range
Mean age, years (s.d.) 62.3 (4.58) 50.5–70.6 62.7 (4.52) 51.3–70.6
Mean PSA level at first test, ngml
 1 (s.d.) 4.6 (1.9) 3.0–17.0
a 4.6 (1.8) 3.0–15.2
a
% Family history of any cancer (n) 53.6 (177) — 51.8 (101) —
% Family history of prostate cancer (n) 8.2 (27) — 8.7 (17) —
% White ethnicity (n) 95.5 (315) — 95.9 (187) —
% Undergoing first biopsy (n) 93.6 (309) — 93.3 (182) —
Abbreviations: ProtecT¼prostate testing for cancer and treatment; PSA¼prostate-specific antigen.
aMen with PSAX20ngml
 1 are excluded from ProtecT study. n¼number
in sample.
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weeks after having received a negative result (time-point 4),
distress relating to prostate cancer testing remained more
prevalent than distress at the time of the PSA test (difference in
mean: 2.42; 95% CI (0.50, 1.15); P¼0.009), with 8.9% of men (16
out of 179) reporting scores of clinical concern. For these IES
results, logistic regression of dichotomised scores supported the
same conclusions, although this sensitivity analysis suggested that
the elevation at the 12-week follow-up assessment could have
arisen by chance (odds ratio (OR): 1.42; 95% CI (0.80, 2.52);
P¼0.23). Feelings of confusion-bewilderment were at a
significantly lower level at the 12-week follow-up than at PSA
testing (difference in mean:  0.73; 95% CI ( 1.26,  0.25);
P¼0.004). Additional analysis of the cohort of men with complete
data available for all four of the assessment time-points (n¼66)
was consistent with the results presented here and the same
conclusions are supported.
None of the demographic or clinical factors recorded at baseline
significantly predicted high distress and anxiety levels at the
subsequent study time-points (with the exception of urinary
hesitancy: OR: 4.76; 95% CI (1.95, 11.62); P¼0.001), although
psychological factors did (Table 4).
Table 2 Mean scores for negative moods and distress, and percentage of men with scores of clinical significance
a
PSA test (time-point 1) Biopsy (time-point 2)
Post-negative result
(time-point 3)
12-week follow-up
(time-point 4)
Questionnaire
and subscale
Mean
(s.d.)
% High scores
(n/N)
Mean
(s.d.)
% High scores
(n/N)
Mean
(s.d.)
% High scores
(n/N)
Mean
(s.d.)
% High scores
(n/N)
POMS tension-anxiety 3.77 (3.48) 10.5 (14/133) 5.07 (4.11) 19.4 (35/180) 3.38 (3.75) 8.9 (26/292) 2.39 (2.89) 4.8 (11/229)
Depression-dejection 2.52 (4.57) 7.5 (10/133) 2.42 (3.65) 5.1 (9/178) 2.40 (4.10) 6.5 (19/292) 1.75 (3.49) 3.1 (7/228)
Anger-hostility 2.94 (3.56) 6.8 (9/132) 2.89 (3.37) 5.6 (10/179) 2.40 (3.43) 6.2 (18/292) 1.89 (2.68) 3.9 (9/229)
Fatigue-inertia 4.44 (4.30) 12.0 (16/133) 3.34 (3.37) 5.0 (9/180) 3.83 (4.19) 7.5 (22/294) 3.44 (3.53) 4.4 (10/229)
Confusion-bewilderment 2.62 (2.67) 8.3 (11/133) 2.56 (2.56) 6.7 (12/178) 2.16 (2.66) 6.9 (20/292) 1.75 (2.19) 4.8 (11/229)
IES distress (total score) 2.35 (4.43) 0.8 (1/129) 11.74 (13.76) 19.3 (33/171) 9.51 (12.32) 16.9 (49/290) 4.88 (8.82) 9.7 (22/227)
Abbreviations: IES¼Impact of Events Scale; POMS¼Profile of Mood States; PSA¼prostate-specific antigen.
aThresholds for clinical scores (see text for definitions): POMS
tension-anxiety 9.0, depression-dejection 9.4, anger-hostility 8.3, fatigue-inertia 10.9, confusion-bewilderment 6.6; IES distress 19.0. n/N¼number of cases/number completing
subscale. Data are cross-sectional at each assessment time-point, from the whole study sample.
Table 3 Mean scores for the longitudinal cohort (those who completed all the questionnaires they were sent)
PSA test (time-point 1) Biopsy (time-point 2)
Post-negative result
(time-point 3)
12-week follow-up
(time-point 4)
Questionnaire
and subscale
Mean
(s.d.)
% High scores
(n/N)
Mean
(s.d.)
% High scores
(n/N)
Mean
(s.d.)
% High scores
(n/N)
Mean
(s.d.)
% High scores
(n/N) P-value
a
POMS tension-anxiety 2.95 (2.83) 4.6 (3/66) 5.02 (4.31) 19.1 (25/131) 3.17 (3.66) 8.8 (17/194) 2.31 (2.77) 3.6 (7/194) o0.001
Depression-dejection 1.72 (2.57) 1.5 (1/65) 2.38 (3.65) 5.5 (7/128) 1.99 (3.62) 5.2 (10/191) 1.60 (3.07) 2.1 (4/191) 0.086
Anger-hostility 2.37 (2.56) 4.6 (3/66) 2.71 (3.31) 5.4 (7/130) 2.18 (3.39) 5.7 (11/194) 1.88 (2.61) 3.6 (7/194) 0.041
Fatigue-inertia 3.42 (3.22) 3.0 (2/66) 3.17 (3.38) 4.6 (6/131) 3.22 (3.56) 4.1 (8/195) 3.24 (3.34) 3.1 (6/195) 0.95
Confusion-bewilderment 2.41 (2.17) 6.1 (4/66) 2.43 (2.49) 7.0 (9/129) 1.88 (2.29) 3.6 (7/193) 1.68 (2.07) 4.2 (8/193) 0.002
IES distress (total score) 2.52 (5.20) 1.7 (1/60) 11.98 (14.23) 21.1 (24/114) 9.84 (12.74) 19.0 (34/179) 4.93 (9.01) 8.9 (16/179) o0.001
Abbreviations: IES¼Impact of Events Scale; POMS¼Profile of Mood States; PSA¼prostate-specific antigen.
aOverall test of differences across all four means. n/N¼number of
cases/number in sample.
Table 4 Predictor variables for high anxiety and psychological distress at biopsy, after receiving a negative biopsy result, and 12 weeks later
Anxiety
a Distress
b
Predictor Time-point N OR (CI) P-value N OR (CI) P-value
Baseline
c tense/anxious mood (2) Biopsy 90 1.34 (1.12–1.61) 0.001 86 1.13 (0.98–1.30) 0.09
(3) Post-negative result 122 1.37 (1.16–1.62) o0.001 117 1.03 (0.91–1.16) 0.65
(4) After 12 weeks 93 1.55 (1.13–2.13) 0.007 93 1.16 (0.95–1.43) 0.15
Baseline
c intrusive thoughts (2) Biopsy 90 1.53 (1.16–2.01) 0.002 87 1.43 (1.11–1.85) 0.006
(3) Post-negative result 122 1.43 (1.17–1.74) 0.001 119 1.17 (1.00–1.36) 0.049
(4) After 12 weeks 94 1.21 (0.98–1.48) 0.07 96 1.21 (1.00–1.45) 0.047
Baseline
c avoidant behaviours (2) Biopsy 85 1.29 (1.07–1.55) 0.008 82 1.23 (1.03–1.48) 0.02
(3) Post-negative result 115 1.31 (1.09–1.57) 0.004 113 1.29 (1.06–1.57) 0.01
(4) After 12 weeks 91 1.06 (0.79–1.42) 0.71 93 1.08 (0.86–1.36) 0.50
Abbreviations: CI¼95% confidence interval; OR¼odds ratio; PSA¼prostate-specific antigen.
aBased on Profile of Mood State tension-anxiety score.
bBased on Impact of
Events Scale total score.
cBaseline mood and distress is that measured at time of initial PSA testing.
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may experience higher distress levels 12 weeks after biopsy, we
retrieved information on any further biopsies the study men had
undergone. Twenty-three men were found to have had a second
biopsy before being sent their 12-week follow-up questionnaires,
of which 17 men returned data for this assessment (73.9%). The
mean IES total scores (s.d., number of men with high scores/
number completing measure) for these 17 men were 1.29 (2.98, 0
out of 7) at time-point 1; 5.00 (4.38, 0 out of 6) at time-point 2; 9.12
(10.75, 3 out of 17) at time-point 3 and 8.53 (11.31, 4 out of 15) at
time-point 4. There was no significant difference between IES
scores at the 12-week follow-up assessment for those who had a
repeat biopsy and those who did not (P¼0.096). Of the total
number of men from the complete cohort who had high distress at
the 12-week follow-up assessment, 18% (4 out of 22) had
undergone a further biopsy.
DISCUSSION
This study shows that most men seem to cope well with a raised
PSA result followed by a negative biopsy. Mean scores for all
the questionnaire scales were relatively low with regard to the
thresholds for clinical significance and the maximum possible
ranges. However, nearly 20% experienced high levels of
tension-anxiety and psychological distress at the time of the
biopsy, as well as 8.9% with high tension-anxiety and 16.9% with
psychological distress immediately after the receipt of a negative
biopsy result. These findings were substantiated in the longitudinal
cohort. Men exhibited significant increases in distress and
tense and anxious moods from baseline to the time of the
biopsy, which then declined somewhat after receipt of a negative
biopsy result, before returning to much lower levels 12 weeks
later. However, distress was significantly more prevalent at
all of the subsequent time-points compared with distress at the
time of the PSA test, and almost 10% reported distress levels
of clinical concern at the 12-week follow-up. Baseline levels
of mood were found to predict levels of distress and anxiety
at the time of biopsy, after the negative biopsy result and 12 weeks
later.
The present investigation was conducted within the ProtecT
study, enabling large numbers of men based in the community to
participate. This detailed quantitative study of the emotional
consequences of prostate cancer testing is the first study of its
kind in the United Kingdom, using more detailed psychological
measures and using a longer follow-up time than one other
study conducted in the Netherlands (Essink-Bot et al, 1998).
However, the study encompasses some limitations. The ‘baseline’
measures were at the time of the initial PSA test, and it could
be argued that negative mood may already have been elevated
at this time, although an earlier investigation in the ProtecT
cohort showed no difference in depressed or anxious mood
between men who responded to an invitation for PSA testing and
those who did not (Avery et al, 2008b). All men had self-selected to
take part in the study initially, which may influence their
psychological response to being tested. An important issue when
interpreting the findings from the longitudinal cohort was that
they were a smaller and select group of men. This had the
advantage of exploring unconfounded comparisons across time,
although external validity was weakened as men who failed to
respond were excluded. Caution is therefore needed before
generalising these results to a wider population. The statistical
methodology chosen did, however, make use of the maximum
data available. The longitudinal cohort included those men who
had already undergone their biopsy just before the current
substudy started, but who completed both of their post-biopsy
questionnaires when invited to do so. These men did not complete
substudy questionnaires at time-points 1 and 2, but as these
data are missing completely at random, their inclusion in the
longitudinal cohort improves precision without introducing
bias. Nevertheless, we acknowledge that these results could
have been strengthened by a longer recruitment period enabling
a larger longitudinal cohort with data available at all four
assessments.
The study findings are reassuring in that most men seemed to
cope well with the seemingly equivocal result of a raised PSA
followed by a negative biopsy result. However, it remains of
concern that nearly 20% suffered high levels of distress at the time
of biopsy and nearly 17% after having received a negative result. In
an earlier longitudinal study of men being screened for prostate
cancer, Gustafsson et al (1995) reported that cortisol level
(indicating the degree of emotional stress) was highest immedi-
ately before being informed of the biopsy result, although levels
decreased somewhat 2 weeks later in those who received a benign
biopsy result. Other studies have concluded that testing for
prostate cancer had little or no effect on men’s psychological
health (Brindle et al, 2006; Awsare et al, 2008). These studies relied
on the Hospital Anxiety and Depression Scale (HADS) (Zigmond
and Snaith, 1983), which was designed to detect clinical cases of
anxiety and depression. Both studies commented on the low
sensitivity of the HADS in the context of prostate cancer testing. In
addition, a longitudinal Dutch screening study reported no
significant adverse effects on psychological health after receipt of
a negative biopsy result (Essink-Bot et al, 1998). This study used a
general measure for anxiety, which also may not have been
sensitive enough to identify men’s concerns in the context of
prostate cancer screening. The findings reported here confirm that
more detailed, specific measures (e.g. POMS and IES) better reflect
the changes in mood and distress in some men as apparent in an
earlier qualitative study (Avery et al, 2008a).
The IES statements at each of the first three time-points
were tailored to focus on specific aspects current for that stage of
the testing process, for example at time-point 1: ‘I had dreams
about the PSA blood test’. The adapted IES statements at the
12-week follow-up (time-point 4) referred to the complete testing
process for example ‘I had dreams about being tested for
prostate cancer’. In contrast, the POMS consisted of an adjective
list of emotions with no direct reference to particular events
in time. The pattern of mood levels over time was similar whether
measured by the IES or POMS, although POMS scores seemed
to return to pre-PSA levels sooner. At every time-point, men
were asked to respond with regard to how they had felt during
the preceding week. However, at the 12-week follow-up, the
prompt to think about the complete testing process may have
triggered memories of earlier mood states. This could have
influenced men’s responses, rather than just reporting on recent
intrusive thoughts and avoidant behaviours that had troubled
them during the previous week. It is possible that distress in some
men 12 weeks after the biopsy could be due to the knowledge that a
negative biopsy result does not necessarily indicate the ‘all clear’.
Further research, preferably qualitative, is required to explore
this issue and other explanations for distress after a negative
biopsy result.
It has previously been shown that older age, a positive family
history, and a higher PSA level did not predict anxiety in men
during testing for prostate cancer (Macefield et al, 2009). In
contrast here, baseline psychological mood was predictive of
distress and anxiety at later stages of the testing process. This
reflects the findings of the Dutch study, where initial high anxiety
levels were maintained during testing (Essink-Bot et al, 1998), and
supports that baseline psychological factors can continue to be
predictive of distress and anxiety after a longer period after
screening.
The findings of this study have clear practical relevance. Despite
its controversy, PSA testing is widespread. These results,
particularly that high levels of distress may be encountered
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men by GPs before they consent to receiving a test. For men
undergoing testing, whether as part of screening, or in primary
or secondary care, the concomitant collection of POMS and IES
data could be used to identify men who are experiencing
tension-anxiety and early distress symptoms at the time of the
PSA test, and thus identify those who might benefit from
additional support and information to prevent this developing
into distress later on (see also Essink-Bot et al, 1998; Awsare et al,
2008).
The intention of this study was to capture men’s psychological
experiences during prostate cancer testing. Focusing on those
who received a negative biopsy result, it revealed that the majority
of men who undergo testing are not significantly adversely
affected, although some men do find the process distressing.
Men should be informed of the risk of distress before agreeing to a
PSA test.
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